Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia
Journal of Investigative Dermatology · 2026-05 · 146 (5) · 1265-1270.e7
DOI: 10.1016/j.jid.2025.09.375 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Investigative Dermatology, 2026-05. Verfasst von Aubrey Martin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA. Hauptthemen laut MEDLINE: Alopecia, Janus Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, LEO Pharma A/S, Scarring Alopecia Foundation.
Abstract (Originalsprache)
BACKGROUND: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia with generally poor prognosis if untreated and no approved treatment options. OBJECTIVE: The aim of this study was to evaluate changes in the molecular signature of FFA lesions after application of delgocitinib cream. Safety, tolerability, and efficacy were also investigated. METHODS: This was a phase 2a, randomized, double-blind, exploratory trial of 20 mg/g delgocitinib cream (2%) versus cream vehicle in patients with FFA. RESULTS: A total of 30 adult females with FFA were randomized to delgocitinib cream (n = 15) or cream vehicle (n = 15). After 12 weeks, expression of the T helper 1-related biomarker CXCL9 was significantly downregulated (-3.10; P < .05), whereas there were nonsignificant reductions in CXCL10 (-2.60; P < .1) and IFN-γ (-1.49; P = .22) in lesions treated with delgocitinib cream but not cream vehicle. Delgocitinib-treated lesions had a small but significant mean improvement in transcriptomic profile (4%; P < .001), whereas lesions treated with cream vehicle worsened (33%). Delgocitinib cream was well-tolerated and associated with improvements in exploratory clinical severity endpoints. LIMITATIONS: Limitations of the trial include small sample size, biomarker analyses only being conducted to week 12, and the exploratory nature of efficacy endpoints. CONCLUSION: Delgocitinib cream resulted in an improvement in the transcriptomic profile of lesions and may have potential as a topical treatment for FFA. This study is registered with NCT05332366.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Innovaderm Research, Montreal, Canada.
- LEO Pharma A/S, Ballerup, Denmark.
- Department of Dermatology, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA; Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: msenna@lahey.org.
Förderung
- Pfizer
- LEO Pharma A/S
- Scarring Alopecia Foundation
- Eli Lilly and Company
Zitieren
APA
Martin, A., Shokrian, N., Kelley, K. J., Correa da Rosa, J., Del-Duca, E., Bissonnette, R., Sørensen, O. E., Nielsen, A. B., Guttman-Yassky, E., & Senna, M. M. (2026). Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. Journal of Investigative Dermatology, 146(5), 1265-1270.e7. https://doi.org/10.1016/j.jid.2025.09.375
Vancouver
Martin A, Shokrian N, Kelley KJ, Correa da Rosa J, Del-Duca E, Bissonnette R, et al. Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia. Journal of Investigative Dermatology. 2026;146(5):1265-1270.e7. doi:10.1016/j.jid.2025.09.375
BibTeX
@article{Martin2026,
author = {Martin, Aubrey and Shokrian, Neda and Kelley, Kristen J and Correa da Rosa, Joel and Del-Duca, Ester and Bissonnette, Robert and Sørensen, Ole E and Nielsen, Anders Bacher and Guttman-Yassky, Emma and Senna, Maryanne Makredes},
title = {Randomized Controlled Trial of the Topical Jak Inhibitor Delgocitinib Cream in Patients with Frontal Fibrosing Alopecia},
journal = {Journal of Investigative Dermatology},
year = {2026},
volume = {146},
number = {5},
pages = {1265--1270.e7},
doi = {10.1016/j.jid.2025.09.375}
}
EUVIMED